Resilient Fresenius stock holds below EUR 47 as analyst consensus points to upside

Fresenius stock is trading just under EUR 47 as of mid-August 2026, while analyst consensus targets suggest double-digit upside potential from current levels and highlight the company’s role as a core European health-care name.

Fresenius SE & Co. KGaA (ISIN DE0005785604) stock is trading just under EUR 47 in mid-August 2026, with a recent CBOE quote showing EUR 46.72 and a modest negative day change of 0.37 percent as of August 18, 2026. This places the shares slightly below their recent levels at the start of the year, where the same dataset indicates a year-to-date decline of 1.69 percent from the January baseline.

Market snapshot and recent trading context

Market data compiled in a recent CBOE overview shows Fresenius shares at EUR 46.72 with a five-day performance of negative 2.62 percent as of August 18, 2026, signaling a short-term consolidation phase after prior gains. The same quote set confirms that the stock’s day move of negative 0.37 percent came against a backdrop of broader European health-care exposures, keeping Fresenius well within its typical trading range. Against analyst targets, the current quote implies notable potential: the average target stands at EUR 55.86, which is 19.54 percent above the last closing price of EUR 46.73, while the highest published target of EUR 63.50 would represent a significantly larger gap from present levels.

Consensus data for Fresenius indicates a clear buy-oriented stance, with 14 analysts contributing to the current recommendation and an overall view categorized as buying. The spread of targets, from a low of EUR 50.00 through the EUR 55.86 median up to EUR 63.50, underscores that expert expectations cluster in a band well above the latest closing price. For investors, the quantified gap between EUR 46.73 and the EUR 55.86 median target is particularly relevant, as it translates into 19.54 percent upside potential if the company delivers on its operational and strategic plans over the coming quarters.

Analyst consensus and valuation backdrop

The analyst consensus presented in the same detailed overview places Fresenius in the health-care facilities and services space, where stable cash flows and recurring treatment volumes are often valued at premium multiples. In this context, the median price target of EUR 55.86 is accompanied by a buy recommendation, while the EUR 50.00 low target still sits above the current market level, suggesting that downside scenarios modeled by the most cautious analysts remain limited relative to today’s quote. When viewed against the EUR 46.73 last closing price referenced in the dataset, even the low target implies a gain of more than EUR 3 per share.

A separate equity portal focuses on valuation metrics and highlights Fresenius as strongly undervalued relative to a broader STOXX Europe 600 comparison, based on a relative four-week performance of plus 12.32 percent versus the index in mid-August 2026. That outperformance, measured over a rolling month, contrasts with the small negative year-to-date change of 1.69 percent cited in the CBOE data, illustrating how the shares have recovered from earlier pressure and now track ahead of the regional benchmark over shorter horizons. For long-term holders, the mix of modest year-to-date weakness and recent relative strength suggests that the stock may be transitioning from a laggard phase into a more constructive trend if operational performance aligns with expectations.

Technical context and index exposure

The accessible sector consensus information lists Fresenius within the health-care facilities and services category and shows the same EUR 46.72 last price with the 5-day and year-to-date changes already noted, reinforcing that the stock’s recent movement has been limited and without extreme volatility. This profile fits the company’s positioning as a major European health-care group with diversified activities in hospital operations, care services, and medical products, where fundamental drivers tend to be secular demographic trends rather than short-lived cyclical swings.

From a technical perspective, the combination of a EUR 46.72 recent quote, a 5-day performance of negative 2.62 percent, and a year-to-date change of negative 1.69 percent implies the shares are trading slightly below levels that some medium-term traders might view as a neutral zone. While no specific 52-week highs or lows are referenced in the current data, the quantified changes over shorter horizons offer a clear picture: short-term consolidation, modest year-to-date softness, and a sizeable gap to the median analyst target. That gap functions as a valuation signal, especially in an environment where health-care names are often sought for defensive qualities.

Representative Fresenius services in health care

As a diversified health-care group, Fresenius is known for its combination of hospital operations, outpatient care services, and involvement in medical products and therapies. The company’s positioning in health-care facilities and services means that much of its revenue is generated from patient treatments, diagnostic procedures, and longer-term care frameworks rather than one-off product sales. In practice, that translates into recurring cash flows and a business model tied closely to demographic aging, chronic disease management, and expanding access to modern medical care in Europe and other regions.

Fresenius also benefits from synergies between operational units, where hospital networks, specialized clinics, and related service offerings can share infrastructure and medical expertise. This integrated approach supports utilization rates and can enhance margins when throughput improves, giving analysts several levers to monitor in their earnings models beyond simple volume growth. For investors, the breadth of services and the company’s scale in the European health-care system mean that Fresenius can act as a core holding in portfolios seeking exposure to long-term health trends while still offering sensitivity to operational efficiency improvements.

Stock level and investor view

Based on the most recent CBOE quote set, Fresenius shares last traded at EUR 46.72 as of August 18, 2026, with the market closed at 5:30 p.m. local exchange time for that session. With a five-day performance of negative 2.62 percent and a year-to-date change of negative 1.69 percent, the stock currently sits modestly below its start-of-year level yet remains well within a historically typical range for a large-cap European health-care issuer. Against the median analyst target of EUR 55.86 and the highest target of EUR 63.50, the present quote underscores that a double-digit percentage upside scenario is embedded in current consensus expectations, making valuation and upcoming operational updates key watchpoints for investors.

Read more

More on Fresenius stock

Fact box

Company: Fresenius SE & Co. KGaA

ISIN: DE0005785604

Ticker: FRE

Exchange: Xetra

Price (as of August 18, 2026, market close): EUR 46.72

Sector / Industry: Health-care facilities and services

Index membership: STOXX Europe 600 Health Care